Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$208.04
▼ $1.86 (-0.9%)
Market data updated: 09/18 08:10 AM
Fundamentals updated: 09/17/2026
News analyzed: 09/18/2026
Market Cap
$20.28B
Day Range
$206.97 - $210.74
52-Week Range
$195.14 - $269.44
Beta
—
Next Earnings
03.11.2026
STE is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-16.3% (1Y)
Strengths: 11/31 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 27.9%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: $166.34 vs. price $208.04 (-20.0%)
Fair Value
Signal tension
Growth scores strong (76/100), but fair-value analysis scores this stock as relatively expensive (38/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
49
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
76
Quality
63
Value
38
Momentum
20
Risk
54
Sentiment
38
Fundamental
72
Institutional
0
Stocks with a similar DNA right now
SCANNING STE...
Recent media coverage of Steris has centered on its upcoming participation in the **Morgan Stanley Healthcare Conference** on September 15, 2026, where CEO Dan Carestio will present. Analysts have debated the company’s stock valuation, noting it trades near fair value with slight overvaluation concerns, despite a modest 11.2% five-year return. Additionally, a minor stock pullback and investor speculation about potential rebounds post-earnings have been highlighted, alongside a brief mention of a U.S. politician’s stock sale unrelated to company performance.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Steris. News trend score: 38. Reason: 6 of the last 20 articles are negative, versus 4 positive.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
30
🎯 Conviction (vs. Emotion)
42
Psychology
88
Fundamentals
72
Technical
20
Valuation
38
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The price rise has far outpaced the actual improvement in fundamental data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price (3M)
+3%
Market Narrative
34
Fundamental Reality
42
Narrative Gap
-8
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior for STE suggests a **herding dynamic**—participants appear to be aligning with peer movements rather than acting on independent signals. The exact price decline (-2.7%) matching peers indicates a collective response, likely driven by shared exposure or sector-wide triggers. Overconfidence (28) hints at lingering optimism from valuation (31% above DCF), though momentum weakness (-5.2% ROC) may temper aggressive bets. The key open question is whether this herding reflects a rational rebalancing or a delayed reaction to broader headwinds, given the narrow narrative-reality gap (5 points).
Updated: 09/09/2026, 03:42 AM
What could change this?
👥 What the crowd believes
"analysts remain somewhat bullish about the stock’s prospects"
"shares now trade close to a fair level rather than offering an obvious discount"
"STERIS shares trade at US$229.65 after a small pullback... with CEO Dan Carestio scheduled to present"
"Dividend Champion, Contender, And Challenger Highlights"
📈 10D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 98/100
🔴 Weakest match
Jesse Livermore — 16/100
🗣️ Why do they disagree?
This stock sparks a sharp divide among methodologies, with the highest scores from technical and long-term value-oriented investors like Samuel Armstrong Nelson (97) and Edgar Lawrence Smith (80), who see it as either oversold or a prime 'buy and hold' candidate. Meanwhile, growth-focused thinkers like Peter Lynch (73) and Morgan Housel (78) also lean positive, praising its growth potential or quiet compounding qualities. However, more cautious or contrarian voices—such as Jesse Livermore (36) and Benjamin Graham (26)—reject it outright, flagging negative trends or failure to meet defensive valuation standards. The middle ground, represented by Fisher (61) and Howard Marks (62), acknowledges strengths but questions whether the stock’s quality or valuation justifies the risk, creating a clear tension between bullish momentum and skeptical fundamental concerns.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 98
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 92
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 80
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟢 79
The kind of quiet compounder a patient holder could actually stick with
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 76
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 75
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 72
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 72
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟢 68
Reasonable capital-preservation profile
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 64
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 62
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 61
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 54
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 27
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 16
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Based on the last 279 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 9 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a trading range, but the picture isn't yet clear enough on the likely direction.
Low confidence
$206.97
Range Bottom
$241.39
Range Top
50
Trading Days in Range
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
44.2%
Operating Margin
18.6%
Net Margin
13.2%
EBITDA Margin
26.8%
ROE
10.9%
ROA
7.3%
ROIC
—
EPS
$7.97
Cash
$439.60M
Total Debt
$1.93B
Current Ratio
2.09
Debt/Equity
0.27
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 4.9.2026 | $0.690 |
| 8.6.2026 | $0.630 |
| 7.6.2026 | $0.630 |
| 17.2.2026 | $0.630 |
| 16.2.2026 | $0.630 |
| 4.9.2025 | $0.630 |
| 3.9.2025 | $0.630 |
| 10.6.2025 | $0.570 |
| 9.6.2025 | $0.570 |
| 20.2.2025 | $0.570 |
| 19.2.2025 | $0.570 |
| 19.11.2024 | $0.570 |
How is Fair Value calculated? →
Current Price
$208.04
Estimated Fair Value (DCF)
$166.34
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-20.0%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
9.4%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 9.4% | $1.06B | $976.12M |
| 2 | 7.7% | $1.15B | $964.36M |
| 3 | 6.0% | $1.21B | $937.45M |
| 4 | 4.2% | $1.27B | $896.42M |
| 5 | 2.5% | $1.30B | $842.96M |
Base FCF (last actual year)
$972.40M
Terminal Value
$20.45B
Present Value of Terminal Value
$13.29B
Enterprise Value
$17.91B
Net Debt
$1.49B
Equity Value
$16.42B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$72.78
Tangible Book Value per Share (Tangible NAV)
$13.87
Sentiment based on basic keywords (not AI) — 4 positive, 10 neutral, 6 negative out of the last 20 articles.
Yahoo · 16.9.2026
SeekingAlpha · 15.9.2026
Yahoo · 4.9.2026
Zacks · 4.9.2026
Simply Wall St. · 3.9.2026
Yahoo · 3.9.2026
Yahoo · 2.9.2026
Simply Wall St. · 2.9.2026
Yahoo · 1.9.2026
GlobeNewswire · 1.9.2026
SeekingAlpha · 28.8.2026
Benzinga · 28.8.2026
Yahoo · 26.8.2026
Barchart · 26.8.2026
Yahoo · 21.8.2026
Zacks · 21.8.2026
Yahoo · 20.8.2026
Zacks · 20.8.2026
Yahoo · 19.8.2026
StockStory · 19.8.2026
Steris (STE) currently has a StockIQ AI score of 49/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
STE currently scores 49/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, STE's estimated fair value is $166.34, which is 20.0% below the current price of $208.04. This is one valuation model among several signals in the fair-value category, not a price target.
STE's technical score is 20/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 27.9%; Free cash flow growth: 25.0%; Net income growth: 27.3%.
Based on the real signals StockIQ computed: Estimated fair value: $166.34 vs. price $208.04 (-20.0%); Calmar: -0.12 (3y annualized return -3.0% / max drawdown 25.8%); Price is below the 50-day average.
Yes — STE has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 2 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Sohi Mohsen | Open Market Sale | 12.8.2026 | 4,058 | -4,058 | $235.78 |
| Sohi Mohsen | Exercise of Derivative Securities | 12.8.2026 | 4,058 | +4,058 | $86.23 |
| Sohi Mohsen | Exercise of Derivative Securities | 12.8.2026 | 4,058 | -4,058 | — |
| Sohi Mohsen | Exercise of Derivative Securities | 12.8.2026 | 28,363 | +4,058 | $86.23 |
| Sohi Mohsen | Exercise of Derivative Securities | 12.8.2026 | 0 | -4,058 | — |
| Sohi Mohsen | Open Market Sale | 12.8.2026 | 24,305 | -4,058 | $235.78 |
| Shah Nirav R | Grant/Award from Employer | 10.8.2026 | 512 | +512 | — |
| Shapiro Louis | Grant/Award from Employer | 10.8.2026 | 1,025 | +1,025 | — |
| Shah Nirav R | Grant/Award from Employer | 10.8.2026 | 1,506 | +1,506 | — |
| Alegria Esther M. | Grant/Award from Employer | 10.8.2026 | 512 | +512 | — |
| Sohi Mohsen | Grant/Award from Employer | 10.8.2026 | 1,099 | +1,099 | — |
| FELDMANN CYNTHIA L | Grant/Award from Employer | 10.8.2026 | 512 | +512 | — |
| HOLLAND CHRISTOPHER S | Grant/Award from Employer | 10.8.2026 | 1,025 | +1,025 | — |
| Martin Paul Edward | Grant/Award from Employer | 10.8.2026 | 512 | +512 | — |
| Sohi Mohsen | Grant/Award from Employer | 10.8.2026 | 1,229 | +1,229 | — |
| Boulud Pierre | Grant/Award from Employer | 10.8.2026 | 1,025 | +1,025 | — |
| FELDMANN CYNTHIA L | Grant/Award from Employer | 10.8.2026 | 1,506 | +1,506 | — |
| Martin Paul Edward | Grant/Award from Employer | 10.8.2026 | 1,506 | +1,506 | — |
| Alegria Esther M. | Grant/Award from Employer | 10.8.2026 | 1,506 | +1,506 | — |
| FELDMANN CYNTHIA L | Grant/Award from Employer | 10.8.2026 | 1,506 | +1,506 | — |
| HOLLAND CHRISTOPHER S | Grant/Award from Employer | 10.8.2026 | 5,989 | +1,025 | — |
| Sohi Mohsen | Grant/Award from Employer | 10.8.2026 | 1,099 | +1,099 | — |
| Sohi Mohsen | Grant/Award from Employer | 10.8.2026 | 8,979 | +1,229 | — |
| FELDMANN CYNTHIA L | Grant/Award from Employer | 10.8.2026 | 8,640 | +512 | — |
| Martin Paul Edward | Grant/Award from Employer | 10.8.2026 | 5,074 | +512 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
2,443,665 shares short as of 2026-08-31 · vs. 3,159,401 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
72.9% of trading volume this week was short selling, vs. 66.8% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology